BioCentury | Mar 3, 2014
Company News

Egenix, TeraDiscoveries deal

...and an autism drug against the same target, eukaryotic translation initiation factor 4E (eIF4E) . TeraDiscoveries...
...than 20% in the two drug candidates. Egenix will provide funding and target data that TeraDiscoveries...
...use to identify and optimize inhibitors for autism and certain cancer indications that overexpress eIF4E. TeraDiscoveries...
BioCentury | Mar 11, 2013
Company News

Quantum Cures computational biology, other news

...Volunteers will be able to download the software at Quantum Cures' website. Drug discovery company TeraDiscoveries Inc....
BioCentury | Dec 6, 2012
Distillery Therapeutics

Indication: Cancer

...of cancer. Pharmacyclics Inc. has the HDAC8 inhibitor PCI-34051 in preclinical development for various cancers. TeraDiscoveries Inc....
Items per page:
1 - 3 of 3
BioCentury | Mar 3, 2014
Company News

Egenix, TeraDiscoveries deal

...and an autism drug against the same target, eukaryotic translation initiation factor 4E (eIF4E) . TeraDiscoveries...
...than 20% in the two drug candidates. Egenix will provide funding and target data that TeraDiscoveries...
...use to identify and optimize inhibitors for autism and certain cancer indications that overexpress eIF4E. TeraDiscoveries...
BioCentury | Mar 11, 2013
Company News

Quantum Cures computational biology, other news

...Volunteers will be able to download the software at Quantum Cures' website. Drug discovery company TeraDiscoveries Inc....
BioCentury | Dec 6, 2012
Distillery Therapeutics

Indication: Cancer

...of cancer. Pharmacyclics Inc. has the HDAC8 inhibitor PCI-34051 in preclinical development for various cancers. TeraDiscoveries Inc....
Items per page:
1 - 3 of 3